Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday. Michael Cherny has ...

Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company ...

The number of bird flu cases has risen to 31 in the U.S. but there is no evidence of person-to-person transmission, the CDC ...

Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS. Read why I ...

The not-for-profit charitable health group of the United Methodist Church will transition its outreach testing to the ...

The California Department of Public Health (CDPH) today reported two more H5 avian influenza infections, both confirmed by ...

Fintel reports that on October 23, 2024, Baird upgraded their outlook for Quest Diagnostics (NYSE:DGX) from Neutral to ...

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

Q3 2024 Earnings Call Transcript October 22, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is ...

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S.

Evercore ISI has recently resumed Quest Diagnostics Inc (DGX) stock rating, as announced on August 28, 2024, according to Finviz. Earlier, on July 10, 2024, Citigroup had raised the stock from a ...